AI could replace biopsies for HER2 testing in bladder cancer
NCT ID NCT07454941
First seen Mar 27, 2026 · Last updated May 24, 2026 · Updated 13 times
Summary
This study enrolls 4,000 people with urothelial carcinoma (bladder cancer) to test whether artificial intelligence can accurately predict HER2 protein levels using MRI scans and tissue images. The goal is to guide targeted therapy decisions without needing invasive biopsies. Researchers will also use AI to help diagnose cancer type and severity.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HER2 are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
National Cancer Center / Cancer Hospital, Chinese Academy of Medical Sciences Beijing
Beijing, Chaoyang District, 100021, China
Conditions
Explore the condition pages connected to this study.